TVTX — Travere Therapeutics, Inc.

Summary of Travere Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: U.S. net product sales reached $126.6 million, with $103.3 million attributed to FILSPARI, marking a 144% year-over-year growth.
• Full Year 2025 Revenue: Total net product sales were $410.5 million, with FILSPARI contributing $322 million.
• Net Income: Reported at $2.7 million ($0.03 per share), a significant improvement from a net loss of $60.3 million in Q4 2024.
• Cash Position: As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $322.8 million.

2. Strategic Updates and Business Highlights

• FILSPARI Performance: Strong demand with 908 new patient start forms in Q4. The product is gaining traction among both new and established prescribers, with a notable increase in use among community nephrologists.
• FSGS Indication: The FDA has set a new PDUFA action date of April 13, 2026, following a major amendment to the sNDA. Travere remains confident in FILSPARI's potential as the first approved treatment for FSGS.
• Pipeline Development: Progress on pegtibatinase for classical homocystinuria (HCU) continues, with the pivotal Phase III HARMONY study resuming site activation.

3. Forward Guidance and Outlook

• 2026 Expectations: Travere anticipates continued growth in FILSPARI sales, with a focus on expanding its role in IgA nephropathy and potential approval in FSGS. The company expects moderate operating expense growth, primarily due to investments in clinical trials and commercial efforts.
• Market Penetration: Current estimates suggest FILSPARI has not yet penetrated 10% of the addressable IgA nephropathy market, indicating significant growth potential.

4. Bad News, Challenges, or Points of Concern

• FDA Review Process: The delay in the FDA's review timeline for the FSGS indication could impact market expectations and investor sentiment.
• Increased Competition: The entry of new therapies, such as Otsuka's APRIL blocker, could introduce competitive pressures in the IgA nephropathy market, although Travere reports no significant switching or sequencing issues at this time.
• Gross to Net Discounts: An anticipated increase in gross to net discounts may impact revenue recognition in the first quarter of 2026.

5. Notable Q&A Insights

• Market Dynamics: The majority of FILSPARI prescriptions are occurring in community settings, reflecting the treatment landscape's shift. The company maintains a strong position in payer formularies, ensuring broad access.
• Clinical Data Comparisons: Management emphasized the robustness of FILSPARI's clinical data versus competitors, particularly regarding long-term nephroprotection and proteinuria reduction.
• Halo Effect: Approval for FSGS could create a positive halo effect, enhancing FILSPARI's adoption in IgA nephropathy due to overlapping prescriber bases.
• Investor Communication: The company plans to enter a quiet period as the FSGS PDUFA date approaches, with updates to follow post-FDA decision.

Overall, Travere Therapeutics demonstrated strong financial performance in Q4 2025, with significant growth in FILSPARI sales and a promising outlook for its pipeline, despite facing challenges from regulatory timelines and increased competition.